ClinicalTrials.gg
CompletedNCT01959243Updated Oct 23, 2019Results posted

Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants

A Phase 3 interventional study of Brimonidine Tartrate and Vehicle in Hyperemia, sponsored by Bausch & Lomb Incorporated. Completed at 4 sites in United States. Open to participants aged 5 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-23.

Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
507
Allocation
Randomized
Ages
5 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies in Hyperemia with a site in United States — 9 open to participants now, 9 under way, 2 of them phase 3. Hyperemia · United States.

Enrollment
3rd of 19
507 · median 68
Started
2014
with 2 others
Phase 3
6 of 23
2 open now
Registered
3rd of 23
by date
Lead sponsor
3 of 23
Bausch & Lomb Incorporated

Among the 23 studies in Hyperemia with a site in United States, this one is the 3rd largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2014, is one of 6 in phase 3, and was the 3rd registered.

Hyperemia

98 studies on the registry are indexed under Hyperemia; 44 are open to participants now.

Browse Hyperemia studies →

Open to participants now

9 of the 23 studies in Hyperemia with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 28 Hyperemia studies recruiting now, 17 (61%) set no upper age limit and 7 (25%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 5 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Hyperemia with a site in United States, or all of them as a file.
02

Study summary

To compare the safety and tolerability of brimonidine tartrate ophthalmic solution 0.025% versus its vehicle in a population of pediatric, adult, and geriatric participants. At least 51% of participants will be 40 years of age or older.

03

Conditions studied

  • Hyperemia

Browse trials for

Keywords

  • Ocular redness
04

Who can participate

Ages eligible
5 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be at least 5 years of age at Baseline (Visit 1) of either sex and any race or ethnicity;
  • Have ocular health within normal limits, including a calculated best-corrected (if necessary) visual acuity of 0.3 logarithm of the minimum angle of resolution (logMAR) or better in each eye, as measured using an Early Treatment of Diabetic Retinopathy Study (ETDRS) chart.

Exclusion criteria

Exclusion Criteria:

  • Have any ocular/systemic health problems
  • Use of any disallowed medications during the period indicated prior to Baseline (Visit 1) and for the duration of the study.
05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
507 participants (actual)

Study arms

  • Experimental
    Brimonidine Tartrate

    Participants will apply 1 drop of brimonidine tartrate ophthalmic solution 0.025% into each eye 4 times daily for up to 4 consecutive weeks.

    Drug: Brimonidine Tartrate · Drug: Sodium Fluorescein · Drug: Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP

  • Placebo comparator
    Brimonidine Tartrate Vehicle

    Participants will apply 1 drop of the vehicle of brimonidine tartrate ophthalmic solution into each eye 4 times daily for up to 4 consecutive weeks.

    Drug: Vehicle · Drug: Sodium Fluorescein · Drug: Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP

Interventions

  • Ophthalmic solution to be applied as directed.

  • DrugVehicle

    Ophthalmic solution to be applied as directed.

  • DrugSodium Fluorescein

    For use as needed during the study for evaluating corneal damage.

  • DrugFluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP

    For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    TEAE is defined as any untoward medical occurrence or undesirable event(s) that begins or worsens following administration of the study drug, whether or not considered related to the treatment by the Investigator. A TEAE is considered serious if, in the view of the Investigator or Sponsor, it results in any of the following outcomes: death, a life-threatening TEAE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, an important medical event that jeopardized the participant and required medical intervention, or sight-threatening (possibly resulting in persistent or significant loss of vision). A summary of other non-serious adverse events (AEs) and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Baseline up to Day 29

Secondary outcomes

  1. Drop Comfort Assessment as Assessed by the Participant

    Drop comfort assessment (0-10 unit scale in which a score of 0 denotes "very comfortable" and 10 is "very uncomfortable") was performed by the participant. Participant's average score across eyes at each time point were used for analysis.

    Time frame: At dose installation, 30 seconds postdose installation, and 1 minute postdose installation on Day 1

  2. Number of Participants Who Were Fully Alert as Assessed by the Investigator on Days 1, 8, 15, and 29

    An alertness evaluation was performed by the Investigator asking the participant and/or participant's parent/legal guardian (pediatric participants only) a few questions based on the previous week. Using those answers, along with his/her clinical opinion, the Investigator made an assessment of the participant's level of alertness using the following 6-point scale: fully alert, alert, lethargy, obtunded, stupor, or coma.

    Time frame: Predose installation on Day 1 and 90-180 minutes postdose installation on Days 1, 8, 15, and 29

07

Results

Posted Oct 23, 2019

Participant flow

Participant flow — Overall Study
MilestoneBrimonidine TartrateBrimonidine Tartrate Vehicle
Started337170
Received at least 1 dose of study drug337170
Completed324166
Not completed134
Withdrew: Investigator decision30
Withdrew: Adverse event52
Withdrew: Administrative reasons21
Withdrew: Lost to follow-up31

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

TEAE is defined as any untoward medical occurrence or undesirable event(s) that begins or worsens following administration of the study drug, whether or not considered related to the treatment by the Investigator. A TEAE is considered serious if, in the view of the Investigator or Sponsor, it results in any of the following outcomes: death, a life-threatening TEAE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, an important medical event that jeopardized the participant and required medical intervention, or sight-threatening (possibly resulting in persistent or significant loss of vision). A summary of other non-serious adverse events (AEs) and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Baseline up to Day 29
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsBrimonidine TartrateBrimonidine Tartrate Vehicle
Participants with at Least 1 TEAE6638
Participants with at Least 1 Ocular TEAE4425
Participants with at least 1 Non-Ocular TEAE2316
Participants with at least 1 Serious TEAE20
Participants Discontinued from Study due to TEAEs52
SecondaryDrop Comfort Assessment as Assessed by the Participant

Drop comfort assessment (0-10 unit scale in which a score of 0 denotes "very comfortable" and 10 is "very uncomfortable") was performed by the participant. Participant's average score across eyes at each time point were used for analysis.

Time frame:
At dose installation, 30 seconds postdose installation, and 1 minute postdose installation on Day 1
Reported as:
Mean · units on a scale
Drop Comfort Assessment as Assessed by the Participant
units on a scaleBrimonidine TartrateBrimonidine Tartrate Vehicle
Upon Dose Installation0.4 ± 0.900.4 ± 0.77
30 Seconds Postdose Installation0.4 ± 0.900.3 ± 0.85
1 Minute Postdose Installation0.4 ± 0.830.4 ± 0.83
SecondaryNumber of Participants Who Were Fully Alert as Assessed by the Investigator on Days 1, 8, 15, and 29

An alertness evaluation was performed by the Investigator asking the participant and/or participant's parent/legal guardian (pediatric participants only) a few questions based on the previous week. Using those answers, along with his/her clinical opinion, the Investigator made an assessment of the participant's level of alertness using the following 6-point scale: fully alert, alert, lethargy, obtunded, stupor, or coma.

Time frame:
Predose installation on Day 1 and 90-180 minutes postdose installation on Days 1, 8, 15, and 29
Reported as:
Count of participants · Participants
Number of Participants Who Were Fully Alert as Assessed by the Investigator on Days 1, 8, 15, and 29
ParticipantsBrimonidine TartrateBrimonidine Tartrate Vehicle
Predose Installation on Day 1337170
Postdose Installation on Day 1336169
Postdose Installation on Day 8326167
Postdose Installation on Day 15326166
Postdose Installation on Day 29323164

Adverse events

Collected over Baseline up to Day 29. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brimonidine Tartrate—2/337 (0.6%)27/337 (8%)
Brimonidine Tartrate Vehicle—0/170 (0%)14/170 (8.2%)
Most frequent serious events
Most frequent serious events
EventBrimonidine TartrateBrimonidine Tartrate Vehicle
GastroenteritisInfections and infestations1/3370/170
Staphylococcal infectionInfections and infestations1/3370/170
SinusitisInfections and infestations1/3370/170
Most frequent other events
Most frequent other events
EventBrimonidine TartrateBrimonidine Tartrate Vehicle
Visual Acuity ReducedEye disorders16/3379/170
Conjunctival HyperaemiaEye disorders11/3376/170

Baseline characteristics

All randomized participants who received at least 1 dose of study drug (Safety Population).

Age, Continuous
Age, Continuous(years)Brimonidine TartrateBrimonidine Tartrate VehicleTotal
Mean40.7 ± 17.1341.0 ± 17.6840.8 ± 17.30
Sex: Female, Male
Sex: Female, Male(Participants)Brimonidine TartrateBrimonidine Tartrate VehicleTotal
Female200100300
Male13770207
08

Study locations

4 sites
  • Bausch Site 3
    Phoenix, Arizona 85032, United States
  • Bausch Site 4
    Havre De Grace, Maryland 21078, United States
  • Bausch Site 1
    Andover, Massachusetts 01810, United States
  • Bausch Site 2
    Philadelphia, Pennsylvania 19148, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2014 to primary completion in Apr 2014, 2 months.

Results were first posted in Oct 2019, 5 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2013
First posted
Oct 9, 2013
StartActual
Feb 22, 2014
Primary completionActual
Apr 23, 2014
CompletionActual
Jun 23, 2014
Results first posted
Oct 23, 2019
Last update
Oct 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01959243
Collaborators
ORA, Inc.
Responsible party
Sponsor
First posted
Oct 9, 2013
Start date
Feb 22, 2014
Primary completion
Apr 23, 2014
Completion
Jun 23, 2014
Results posted
Oct 23, 2019
Last update
Oct 23, 2019

Study contacts

Heleen DeCory
study director · Bausch & Lomb Incorporated

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brimonidine

Start the discussion